Organic Active Ingredients TRIZ Cases

Combines anti-HER2 antibody-drug conjugates with ATM inhibitors to achieve superior antitumor efficacy while reducing dose-dependent toxicity.

A combination therapy comprising PI3K, AKT, and mTOR inhibitors with 4-quinolinemethanols targets the signaling pathway.

Combining beta-catenin inhibitors with immunotherapy agents converts non-inflamed tumors into inflamed phenotypes.

Acidified oral films with benzalkonium chloride boost psilocybin permeation, bypassing first-pass metabolism to improve bioavailability and reduce side effects.

Beta-carotene quenches singlet oxygen in juice, preventing photo-oxidation of fatty acids that causes fishy taste.

Lowering ADC formulation pH to 4.0-4.5 reduces reversible self-association, enhancing stability and potency.

A sulfonylurea ring substituted monocyclic beta-lactam compound exhibits specific crystal form A with high physical and chemical stability.

Selective FXIa inhibition reduces thrombotic events while minimizing bleeding risks compared to traditional FXa inhibitors.

Derivatized collagen-hyaluronic acid implants deliver ocular drugs via rate-controlling barriers, eliminating frequent dosing burdens.

VBXYP-P crosses the blood-brain barrier to deliver nucleic acids to glioblastoma multiforme cells while minimizing cytotoxicity.

Magnetic guidance of a metal-salen complex delivers antitumor drugs to tumors, reducing adverse reactions in normal tissues.

Deoxygenated water and oxygen scavengers protect superoxide dismutase from reactive oxygen species degradation during storage.

Synthetic formulas incorporating human milk oligosaccharides dampen virus-induced inflammation in infants.

Biocompatible polymer nanoparticles coated with cationic polymers adsorb NFκB decoy oligonucleotides for efficient cellular delivery.

Locked nucleic acid DNA oligonucleotides inhibit SARS-CoV-2 replication at low doses, reducing host cell cytotoxicity.

Small molecule liver X receptor modulators disrupt cancer cell metabolism to induce selective tumor death.

Two-carbon linked artemisinin trioxane dimers resolve short half-life and resistance issues by merging active units into stable molecules.

Histidine betaine acts as an intermediary mediator to reduce inflammation and metabolic dysfunction in aging.

Small molecule RXFP1 agonists resolve peptide limitations by enabling oral bioavailability and extending half-life for cardiovascular treatment.

A composition using PTB inhibition agents and miR-9 to reprogram non-neuronal cells into functional neurons.

Crystalline esylate and L-malate salts of Linsitinib resolve poor pH-related solubility.

Specific PCNA inhibitors target cancer-associated isoforms to treat diseases without significant side effects.

Preliminary HBsAg administration primes the immune response, improving treatment efficacy and viral clearance rates in chronic hepatitis B patients.

Formula I macrocyclic compounds reduce viral load and clear RNA, addressing toxicity limits in existing hepatitis C treatments.

Pyrrolopyridazine compounds selectively block Kv1.5, Kv1.3, and Kv1.1 channels to prevent nephrotoxicity and neurotoxicity from traditional immunosuppressants.

A specialized SGLT2 inhibitor composition reduces renal hyperfiltration through targeted glucose excretion.

Novel N4-substituted decitabine analogs enable nebulized pulmonary delivery.

A pharmaceutical composition combines N,N-dimethyltryptamine and harmine within a lipid-based carrier system for non-peroral administration.

A triple combination formulation enhances vorinostat plasma exposure and brain penetration through inclusion complexation.

A chocolate delivery system incorporates masking agents to conceal bitter active pharmaceutical ingredients within a stable matrix.

A pyrazoloquinazoline compound inhibits CDK and TRKA kinases to treat thymoma.

Spiropiperidine compounds activate GPR40 receptors to boost insulin secretion while avoiding PPAR gamma modulation that causes hypoglycemia and liver damage.

Antisense oligonucleotides induce exon skipping in SOD1 pre-mRNA to trigger cellular degradation of toxic transcripts.

Pharmaceutical compositions comprising specific compounds treat oral infectious diseases while preventing progression of Candida infections.

Lecithin gel carries adamantyl methoxydiphenyl propenoic acid across the skin barrier to reduce comedones while minimizing irritation.

Naphthalene acetic acid derivatives inhibit HIV replication via integrase targeting, bypassing toxicity and resistance from reverse transcriptase drugs.

Albumin-stabilized nanoparticles bypass chemotherapy resistance in hepatocellular carcinoma by exploiting albumin uptake pathways.

Selective oxidation removes pentasaccharide sequences from heparin chains, lowering bleeding risks while maintaining therapeutic efficacy.

5-amino-oxazepine compounds reduce beta-amyloid plaque deposition by modulating beta-secretase activity.